[HTML][HTML] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - Springer
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - infona.pl
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis journal, 2014 - pubmed.ncbi.nlm.nih.gov
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - go.gale.com
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - search.proquest.com
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

[HTML][HTML] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - ncbi.nlm.nih.gov
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.

S Harder - Thrombosis Journal, 2014 - europepmc.org
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

[HTML][HTML] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - Thrombosis Journal, 2014 - thrombosisjournal.biomedcentral …
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

[PDF][PDF] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - 2014 - cyberleninka.org
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

[PDF][PDF] Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism

S Harder - 2014 - thrombosisjournal.biomedcentral …
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …